The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors

The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors

Abstract Background Sodium glucose cotransporter 2 inhibitor (SGLT2i) reduces the risk of hard cardiovascular endpoints in type 2 diabetes mellitus (T2DM) patients with/without established cardiovascular diseases. Whether SGLT2i is associated with a lower risk of new-onset atrial fibrillation (AF) i...

Full description

Bibliographic Details
Main Authors: Ann Wan-Chin Ling, Cze-Ci Chan, Shao-Wei Chen, Yi-Wei Kao, Chien-Ying Huang, Yi-Hsin Chan, Pao-Hsien Chu
Format: Article
Language:English
Published: BMC 2020-11-01
Series:Cardiovascular Diabetology
Subjects:
Atrial fibrillation
Type 2 diabetes mellitus
Sodium glucose cotransporter-2 inhibitor
Dipeptidyl peptidase-4 inhibitor
Heart failure
Online Access:http://link.springer.com/article/10.1186/s12933-020-01162-w

Internet

http://link.springer.com/article/10.1186/s12933-020-01162-w

Similar Items